BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250806T222237EDT-6973jx6Hwh@132.216.98.100
DTSTAMP:20250807T022237Z
DESCRIPTION:Diverse Applications of mRNA-LNP Technology - Register here!\n
 \nDate: March 27\, 2024\n\nTime: 8:30 - 11:30 AM ET\n\nLocation: ɬÀï·¬ En
 gine Centre (FDA 5)\n\nKindly note that the seats are limited and the prio
 rity registration will be given to ɬÀï·¬ RNA community. We will confirm s
 uccessful registrations by email prior to the seminar.\n\n\nSpeakers:\n\nD
 r. Nedim Emil Altaras is the current leader of Technical Development at Mo
 derna\, where he has a distinguished track record that spans over 20 years
  in the field of vaccines and biologics. He has played key roles in overse
 eing Global Product\, Development\, Manufacturing\, Supply Chain\, and Ope
 rations teams. His roles at Moderna have included Head of External Manufac
 turing and CMC Vaccines lead.\n\nPrior to his current role\, Dr. Altaras w
 as responsible for setting up the manufacturing operations at Seres Therap
 eutics\, which focused on the production of new live biologics for microbi
 ome therapeutics. His career commenced at Merck & Co.\, Inc. in Bioprocess
  R&D\, where he supported the development of various early-stage vaccine c
 andidates. He held several significant positions during his tenure at Merc
 k\, leading the Fermentation and Cell Culture Development and overseeing d
 evelopment teams for multiple vaccine programs. Later\, he moved into the 
 Manufacturing division\, where he established the value-chain management f
 or various vaccine products and led the creation of manufacturing and supp
 ly chain operations for a partnership product.\n\nDr. Altaras's educationa
 l background includes a Bachelor of Engineering from ɬÀï·¬\, a
 warded in 1994\, and a Ph.D. in Chemical Engineering from the University o
 f Wisconsin-Madison\, completed in 1999. He also holds a Master's degree i
 n Organizational Dynamics from the University of Pennsylvania\, obtained i
 n 2014.\n\n\nDr. Amy Rabideau is a Fellow and the Technical Lead for Early
  Development at Moderna. In this role\, she leads a cross functional team 
 focused on defining and characterizing the processes used to manufacture t
 he products advancing into the clinic. Amy previously led the Early Phase 
 mRNA process development team at Moderna\, responsible for defining and im
 plementing mRNA processes for Moderna’s Early Phase portfolio. She led a t
 eam of scientists and engineers in advancing our understanding of RNA proc
 ess development\, characterizing the product and process related impuritie
 s\, and devising production strategies to reduce immunostimulatory impurit
 y formation\, including engineering T7 RNA polymerases. Prior to her 8.5 y
 ear tenure at Moderna\, Amy completed her PhD in Biological Chemistry at M
 IT and her BS in Chemistry and Biology at Syracuse University.\n
DTSTART:20240327T123000Z
DTEND:20240327T153000Z
SUMMARY:Technical Seminar: Diverse Applications of mRNA-LNP Technology
URL:/engine/channels/event/technical-seminar-diverse-a
 pplications-mrna-lnp-technology-355947
END:VEVENT
END:VCALENDAR